Udo Gaipl

Prof. Dr. Udo Gaipl

Translational Radiobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
Niloy Ranjan DattaNiloy Ranjan Datta
Niloy Ranjan Datta
SOS. Gómez Ordóñez
S. Gómez Ordóñez
Udo GaiplUdo Gaipl
Udo Gaipl
Margarethus PaulidesMargarethus Paulides
Margarethus Paulides
HCH. Crezee
H. Crezee
Stephan BodisStephan Bodis
Stephan Bodis

24 April 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
NTNarges Tajik
Narges Tajik
MFMichael Frech
Michael Frech
OSOscar Schulz
Oscar Schulz
FSFabian Schälter
Fabian Schälter
SLSébastien Lucas
Sébastien Lucas
Mario ZaissMario Zaiss
Mario Zaiss
Gut microbial dysbiosis is associated with the development of autoimmune disease, but the mechanisms by which microbial dysbiosis affects the transition from asymptomatic autoimmunity to inflammatory disease are incompletely characterized. Here, we identify intestinal barrier integrity as an important checkpoint in translating autoimmunity to inflammation. Zonulin family peptide (zonulin), a potent regulator for intestinal tight junctions, is highly expressed in autoimmune mice and humans and can be used to predict transition from autoimmunity to inflammatory arthritis. Increased serum zonulin levels are accompanied by a leaky intestinal barrier, dysbiosis and inflammation. Restoration of the intestinal barrier in the pre-phase of arthritis using butyrate or a cannabinoid type 1 receptor agonist inhibits the development of arthritis. Moreover, treatment with the zonulin antagonist larazotide acetate, which specifically increases intestinal barrier integrity, effectively reduces arthritis onset. These data identify a preventive approach for the onset of autoimmune disease by specifically targeting impaired intestinal barrier function.

30 November 2009 in Molecules
Verified
Journal Article
Open access
PDF file
RCRicardo A. Chaurio
Ricardo A. Chaurio
CJChristina Janko
Christina Janko
Luis MunozLuis Munoz
Luis Munoz
Benjamin FreyBenjamin Frey
Benjamin Frey
Martin HerrmannMartin Herrmann
Martin Herrmann
Udo GaiplUdo Gaipl
Udo Gaipl
Phosphatidylserine (PS), a phospholipid predominantly found in the inner leaflet of eukaryotic cellular membranes, plays important roles in many biological processes. During apoptosis, the asymmetric distribution of phospholipids of the plasma membrane gets lost and PS is translocated to the outer leaflet of the plasma membrane. There, PS acts as one major “eat me” signal that ensures efficient recognition and uptake of apoptotic cells by phagocytes. PS recognition of activated phagocytes induces the secretion of anti-inflammatory cytokines like interleukin-10 and transforming grow factor-beta. Deficiencies in the clearance of apoptotic cells result in the occurrence of secondarily necrotic cells. The latter have lost the membrane integrity and release immune activating danger signals, which may induce inflammatory responses. Accumulation of dead cells containing nuclear autoantigens in sites of immune selection may provide survival signals for autoreactive B-cells. The production of antibodies against nuclear structures determines the initiation of chronic autoimmunity in systemic lupus erythematosus. Since PS on apoptotic cells is an important modulator of the immune response, natural occurring ligands for PS like annexinA5 have profound effects on immune responses against dead and dying cells, including tumour cells. In this review we will focus on the role of PS exposure in the clearance process of dead cells and its implications in clinical situations where apoptosis plays a relevant role, like in cancer, chronic autoimmunity, and infections. Relevance of other phospholipids during the apoptosis process is also discussed.

13 October 2017 in Immunological Reviews
Verified
Journal Article
Closed access
BFBenjamin Frey
Benjamin Frey
Michael RückertMichael Rückert
Michael Rückert
Lisa Weissmann (née Deloch)Lisa Weissmann (née Deloch)
Lisa Weissmann (née Deloch)
PRPaul F. Rühle
Paul F. Rühle
ADAnja Derer
Anja Derer
Udo GaiplUdo Gaipl
Udo Gaipl

21 November 2015 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
ADAnja Derer
Anja Derer
Benjamin FreyBenjamin Frey
Benjamin Frey
RFRainer Fietkau
Rainer Fietkau
Udo GaiplUdo Gaipl
Udo Gaipl

26 November 2014 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
PDF file
RWR Wunderlich
R Wunderlich
AEA Ernst
A Ernst
FRF Rödel
F Rödel
RFR Fietkau
R Fietkau
Oliver J. OttOliver J. Ott
Oliver J. Ott
Udo GaiplUdo Gaipl
Udo Gaipl